Causes of Elevated Platelets (Thrombocytosis)
Elevated platelet count (thrombocytosis, defined as platelets ≥450 × 10³/μL) is predominantly secondary (reactive) in 83% of cases, with primary causes accounting for only 12.5% of patients. 1, 2
Primary (Clonal) Thrombocytosis
Primary thrombocytosis results from myeloproliferative neoplasms (MPNs), most commonly:
- Essential thrombocythemia (ET) - the predominant primary cause
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF)
- Other chronic myeloid neoplasms
Among patients with primary thrombocytosis, 86% have at least one molecular marker indicative of MPNs (JAK2, CALR, or MPL gene mutations) 2. The JAK2V617F mutation is particularly common in ET and PV 3, 4.
Primary thrombocytosis carries significantly higher thrombotic risk and higher median platelet counts compared to secondary causes 2.
Secondary (Reactive) Thrombocytosis
Secondary thrombocytosis accounts for the vast majority of cases and has distinct etiologies depending on clinical setting:
Most Common Causes Overall:
- Tissue injury/surgical complications (32-54%) - particularly in inpatients
- Infections (17%)
- Chronic inflammatory disorders (12%)
- Iron deficiency anemia (11%)
- Splenectomy or splenic sequestration 2, 5
Inpatient vs Outpatient Patterns:
Inpatients predominantly have:
- Surgical complications (72%)
- Concurrent/previous splenectomy (51%)
- Infections (45%) 5
Outpatients more commonly have:
- Hematologic malignancies (57%)
- Iron deficiency (37%)
- Previous splenectomy (28%) 5
Additional Secondary Causes:
- Malignancy (solid tumors - paraneoplastic)
- Acute hemorrhage
- Hemolysis
- Medications (all-trans retinoic acid, epinephrine, G-CSF)
- Recovery from bone marrow suppression
- Rebound thrombocytosis after chemotherapy 6, 7
Key Diagnostic Distinctions
The setting matters critically: Hematologic malignancy is 3.4 times more likely to cause thrombocytosis in outpatients versus inpatients (57% vs 17%) 5.
Extreme thrombocytosis (platelets >1000 × 10³/μL) is multifactorial in 79% of cases, with surgical complications and hematologic malignancies being the dominant causes 5. Paradoxically, extreme thrombocytosis (>1000 × 10³/μL) in ET is associated with acquired von Willebrand disease and bleeding tendency rather than thrombosis, and may actually correlate with lower thrombosis rates 4.
Clinical Implications
Secondary thrombocytosis rarely causes vascular complications and typically resolves with treatment of the underlying condition - 84% of cases resolve within 30 days 5, 6. In contrast, primary thrombocytosis requires specific risk stratification using the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-Thrombosis) to guide management 4, 1.
Occult hematologic malignancies are uncommon (12.5% overall, with only 8.2% in inpatients) when other major causes of thrombocytosis are present 2, 5. However, new malignancy diagnoses are 1.9 times more likely in outpatients than inpatients.